Daniel Barenboim, Parkinson's disease
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.
The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...
We spend billions searching for the cures to chronic illnesses while neglecting research that could make the daily lives of ...
WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...
The Google cofounder has donated more than $1.5 billion to Parkinson’s research. Now, as he takes on autism, he’s also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback